Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: A SEER-medicare analysis

Robert Eil, Brian S. Diggs, Samuel Wang, James Dolan, John Hunter, Charles Thomas

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND The survival impact of neoadjuvant chemoradiotherapy (CRT) on esophageal cancer remains difficult to establish for specific patients. The aim of the current study was to create a Web-based prediction tool providing individualized survival projections based on tumor and treatment data. METHODS Patients diagnosed with esophageal cancer between 1997 and 2005 were selected from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The covariates analyzed were sex, T and N classification, histology, total number of lymph nodes examined, and treatment with esophagectomy or CRT followed by esophagectomy. After propensity score weighting, a log-logistic regression model for overall survival was selected based on the Akaike information criterion. RESULTS A total of 824 patients with esophageal cancer who were treated with esophagectomy or trimodal therapy met the selection criteria. On multivariate analysis, age, sex, T and N classification, number of lymph nodes examined, treatment, and histology were found to be significantly associated with overall survival and were included in the regression analysis. Preoperative staging data and final surgical margin status were not available within the SEER-Medicare data set and therefore were not included. The model predicted that patients with T4 or lymph node disease benefitted from CRT. The internally validated concordance index was 0.72. CONCLUSIONS The SEER-Medicare database of patients with esophageal cancer can be used to produce a survival prediction tool that: 1) serves as a counseling and decision aid to patients and 2) assists in risk modeling. Patients with T4 or lymph node disease appeared to benefit from CRT. This nomogram may underestimate the benefit of CRT due to its variable downstaging effect on pathologic stage. It is available at skynet.ohsu.edu/ nomograms. Cancer 2014;120:492-498.

Original languageEnglish (US)
Pages (from-to)492-498
Number of pages7
JournalCancer
Volume120
Issue number4
DOIs
StatePublished - Feb 15 2014

Fingerprint

Nomograms
Chemoradiotherapy
Esophageal Neoplasms
Medicare
Epidemiology
Esophagectomy
Lymph Nodes
Survival
Histology
Logistic Models
Databases
Propensity Score
Decision Support Techniques
Therapeutics
Patient Selection
Counseling
Neoplasms
Multivariate Analysis
Regression Analysis

Keywords

  • chemoradiotherapy
  • esophageal cancer
  • neoadjuvant
  • nomogram
  • predictive tool

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer : A SEER-medicare analysis. / Eil, Robert; Diggs, Brian S.; Wang, Samuel; Dolan, James; Hunter, John; Thomas, Charles.

In: Cancer, Vol. 120, No. 4, 15.02.2014, p. 492-498.

Research output: Contribution to journalArticle

@article{381866b623834e428adc01b5b82a1dc1,
title = "Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: A SEER-medicare analysis",
abstract = "BACKGROUND The survival impact of neoadjuvant chemoradiotherapy (CRT) on esophageal cancer remains difficult to establish for specific patients. The aim of the current study was to create a Web-based prediction tool providing individualized survival projections based on tumor and treatment data. METHODS Patients diagnosed with esophageal cancer between 1997 and 2005 were selected from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The covariates analyzed were sex, T and N classification, histology, total number of lymph nodes examined, and treatment with esophagectomy or CRT followed by esophagectomy. After propensity score weighting, a log-logistic regression model for overall survival was selected based on the Akaike information criterion. RESULTS A total of 824 patients with esophageal cancer who were treated with esophagectomy or trimodal therapy met the selection criteria. On multivariate analysis, age, sex, T and N classification, number of lymph nodes examined, treatment, and histology were found to be significantly associated with overall survival and were included in the regression analysis. Preoperative staging data and final surgical margin status were not available within the SEER-Medicare data set and therefore were not included. The model predicted that patients with T4 or lymph node disease benefitted from CRT. The internally validated concordance index was 0.72. CONCLUSIONS The SEER-Medicare database of patients with esophageal cancer can be used to produce a survival prediction tool that: 1) serves as a counseling and decision aid to patients and 2) assists in risk modeling. Patients with T4 or lymph node disease appeared to benefit from CRT. This nomogram may underestimate the benefit of CRT due to its variable downstaging effect on pathologic stage. It is available at skynet.ohsu.edu/ nomograms. Cancer 2014;120:492-498.",
keywords = "chemoradiotherapy, esophageal cancer, neoadjuvant, nomogram, predictive tool",
author = "Robert Eil and Diggs, {Brian S.} and Samuel Wang and James Dolan and John Hunter and Charles Thomas",
year = "2014",
month = "2",
day = "15",
doi = "10.1002/cncr.28447",
language = "English (US)",
volume = "120",
pages = "492--498",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer

T2 - A SEER-medicare analysis

AU - Eil, Robert

AU - Diggs, Brian S.

AU - Wang, Samuel

AU - Dolan, James

AU - Hunter, John

AU - Thomas, Charles

PY - 2014/2/15

Y1 - 2014/2/15

N2 - BACKGROUND The survival impact of neoadjuvant chemoradiotherapy (CRT) on esophageal cancer remains difficult to establish for specific patients. The aim of the current study was to create a Web-based prediction tool providing individualized survival projections based on tumor and treatment data. METHODS Patients diagnosed with esophageal cancer between 1997 and 2005 were selected from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The covariates analyzed were sex, T and N classification, histology, total number of lymph nodes examined, and treatment with esophagectomy or CRT followed by esophagectomy. After propensity score weighting, a log-logistic regression model for overall survival was selected based on the Akaike information criterion. RESULTS A total of 824 patients with esophageal cancer who were treated with esophagectomy or trimodal therapy met the selection criteria. On multivariate analysis, age, sex, T and N classification, number of lymph nodes examined, treatment, and histology were found to be significantly associated with overall survival and were included in the regression analysis. Preoperative staging data and final surgical margin status were not available within the SEER-Medicare data set and therefore were not included. The model predicted that patients with T4 or lymph node disease benefitted from CRT. The internally validated concordance index was 0.72. CONCLUSIONS The SEER-Medicare database of patients with esophageal cancer can be used to produce a survival prediction tool that: 1) serves as a counseling and decision aid to patients and 2) assists in risk modeling. Patients with T4 or lymph node disease appeared to benefit from CRT. This nomogram may underestimate the benefit of CRT due to its variable downstaging effect on pathologic stage. It is available at skynet.ohsu.edu/ nomograms. Cancer 2014;120:492-498.

AB - BACKGROUND The survival impact of neoadjuvant chemoradiotherapy (CRT) on esophageal cancer remains difficult to establish for specific patients. The aim of the current study was to create a Web-based prediction tool providing individualized survival projections based on tumor and treatment data. METHODS Patients diagnosed with esophageal cancer between 1997 and 2005 were selected from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. The covariates analyzed were sex, T and N classification, histology, total number of lymph nodes examined, and treatment with esophagectomy or CRT followed by esophagectomy. After propensity score weighting, a log-logistic regression model for overall survival was selected based on the Akaike information criterion. RESULTS A total of 824 patients with esophageal cancer who were treated with esophagectomy or trimodal therapy met the selection criteria. On multivariate analysis, age, sex, T and N classification, number of lymph nodes examined, treatment, and histology were found to be significantly associated with overall survival and were included in the regression analysis. Preoperative staging data and final surgical margin status were not available within the SEER-Medicare data set and therefore were not included. The model predicted that patients with T4 or lymph node disease benefitted from CRT. The internally validated concordance index was 0.72. CONCLUSIONS The SEER-Medicare database of patients with esophageal cancer can be used to produce a survival prediction tool that: 1) serves as a counseling and decision aid to patients and 2) assists in risk modeling. Patients with T4 or lymph node disease appeared to benefit from CRT. This nomogram may underestimate the benefit of CRT due to its variable downstaging effect on pathologic stage. It is available at skynet.ohsu.edu/ nomograms. Cancer 2014;120:492-498.

KW - chemoradiotherapy

KW - esophageal cancer

KW - neoadjuvant

KW - nomogram

KW - predictive tool

UR - http://www.scopus.com/inward/record.url?scp=84893727923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893727923&partnerID=8YFLogxK

U2 - 10.1002/cncr.28447

DO - 10.1002/cncr.28447

M3 - Article

C2 - 24194477

AN - SCOPUS:84893727923

VL - 120

SP - 492

EP - 498

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -